Press Releases
Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company
November 9, 2021
Strategic Decision Based Upon Recent Business Success and Plans to Support Continued Growth and Investments in OmniAb’s Drug Discovery Platform Conference Call…
Press Releases
Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent...
August 30, 2021
First regulatory approval of an OmniAb-derived antibody EMERYVILLE, Calif.–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Gloria Biosciences (GloriaBio) has…
Press Releases
GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb Licensing Agreement
June 2, 2021
NANJING, China and SAN DIEGO, June 2, 2021 /PRNewswire/ — GenScript Biotech Corporation (HKG: 1548) along with its subsidiary, GenScript ProBio, and Ligand Pharmaceuticals Incorporated…
Press Releases
Ligand Announces Clinical and Regulatory Progress by Multiple Partners with OmniAb Antibodies
November 23, 2020
Two large pharma partners reach clinical-development milestones with OmniAb-derived antibody programs and Ligand earns $4.5 million in milestone payments…
Press Releases
Ligand Expands OmniAb Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences
September 10, 2020
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of two privately held companies that strengthen…
Press Releases
Ligand OmniAb Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of...
August 25, 2020
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) OmniAb partner Immunovant, Inc. (NASDAQ: IMVT) announced positive topline results from…
Press Releases
CStone Announces That OmniAb-derived CS1001 (Anti-PD-L1) Phase 3 Trial Met the Primary Endpoint as First-Line...
August 7, 2020
CS1001 is the first anti-PD-L1 mAb to demonstrate overwhelming efficacy as First Line treatment of Stage IV squamous and non-squamous NSCLC in a randomized, double-blind Phase…
Press Releases
Ligand’s Technologies Support and Enable Potential Coronavirus Treatments
February 3, 2020
Partner Gilead Sciences’ Captisol-enabled remdesivir (GS-5734) highlighted in the New England Journal of Medicine for treating the first case of the 2019 novel coronavirus in…
Press Releases
Ligand Enters into OmniAb Platform License Agreement with Pandion Therapeutics
January 13, 2020
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb license agreement with Pandion Therapeutics…
Press Releases
Ligand Enters into Worldwide OmniAb Platform License Agreement with Sanofi
December 2, 2019
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb license agreement with Sanofi…
Press Releases
Ligand Acquires Ab Initio Biotherapeutics, an Antigen-Discovery Company
July 23, 2019
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of an agreement with Ab Initio Biotherapeutics whereby Ligand…
Press Releases
Ligand Announces OmniAb Partnership with Genagon Therapeutics
February 7, 2019
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb partnership with Genagon Therapeutics AB…